Cost Effectiveness Analysis of Nilotinib Versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia from the Health Insurance Perspective in Egypt
Abstract
Authors
aS Abourawash R Eldessouky gH Elsisi
aS Abourawash R Eldessouky gH Elsisi
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now